[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561663":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":34,"centralContacts":38,"locations":43,"responsibleParty":61,"collaborators":64,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":29,"enrollmentInfo":78,"targetDuration":29,"studyType":81,"phases":82,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":46,"whyStopped":29,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"phase 1","EXPERIMENTAL","After completing screening questions and obtaining consent, eligible participants will complete their baseline procedures and measures. All participants will then start the experimental, i.e., bundled intervention, the first week after their ED discharge, including peer support service and buprenorphine treatment with addiction physicians using telehealth. Each participant will be in the study for 3 months. During the study period, participants will be sent survey links to their cell phones and\u002For emails to complete self-report questionnaires via the Research Electronic Data Capture (REDCap) at 1-month and 3-month for follow-up assessments. Peers will remind the participants to complete the survey.",[13],"Other: a bundled intervention",{"label":15,"type":10,"description":16,"interventionNames":17},"phase 2- experimental","Participants will be enrolled the same way as in phase 1. After their enrollment, participants will be randomized to either the experimental (bundled intervention) group or the control (usual care group). Bundled intervention will have the same components as in the phase 1, including peer support, buprenorphine treatment, and telehealth up to 3 months after ED\u002Fhospital discharge, and linkage to definitive addiction treatment programs. Participants will be sent survey links to their cell phones and emails to complete self-report questionnaires via REDCap at 1- and 3-month for follow-up assessments. Participants will be reminded via text messages and\u002For emails to complete the survey twice per day 5 days prior to their follow-up assessments.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"phase 2- control","PLACEBO_COMPARATOR","Participants who are randomized to the control group will receive the usual care that has been established in the ED at UAB hospital. The current usual care at the UAB ED includes a thorough assessment, buprenorphine initiation as appropriate, peer referral, and a written list of buprenorphine clinics. Participants will also receive information about community-based substance use treatment programs. However, these services are at the participant's own discretion to navigate and attend after ED discharge. Participants will be sent survey links to their cell phones and emails to complete self-report questionnaires via REDCap at 1- and 3-month for follow-up assessments. Participants will be reminded via text messages and\u002For emails to complete the survey twice per day 5 days prior to their follow-up assessments.",[23],"Other: control group",[25,30],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"a bundled intervention","a bundled intervention, including peer support, buprenorphine (ranging from 4mg-24mg, oral, daily), telehealth, and community-based addiction programs.",[9,15],null,{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"control group","participants will not be intervened with this bundled treatment, but continue the usual care that has been established at UAB ED.",[19],[35],{"name":36,"affiliation":5,"role":37},"Li Li, MD;PhD","PRINCIPAL_INVESTIGATOR",[39],{"name":36,"role":40,"phone":41,"phoneExt":29,"email":42},"CONTACT","2059346269","liyli@uabmc.edu",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"UAB","RECRUITING","Birmingham","Alabama","35294","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-86.80249,33.52066,{"lat":56,"lon":55},[59,60],{"name":36,"role":40,"phone":41,"phoneExt":29,"email":42},{"name":36,"role":37,"phone":29,"phoneExt":29,"email":29},{"type":37,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Li Li","Full Professor",[65],{"name":66,"class":67},"National Institute on Drug Abuse (NIDA)","NIH","100561663","phase-1-a-bundled-intervention-100561663",false,"NCT06593093","A Bundled Intervention","A Bundled Intervention to End Opioid Overdose by Increasing Treatment Uptake Post Emergency Department Discharge","B-CARE","Inclusion Criteria:\n\n1. discharged from the ED and inpatient settings at the UAB hospital\n2. 19 years or older (the age of majority in Alabama);\n3. diagnosis of OUD and experiencing opioid overdose in the last 12 months;\n4. prescribed buprenorphine in the ED and willing to continue buprenorphine post-ED discharge;\n5. English speaking;\n6. not actively psychotic and suicidal, or cognitively impaired.\n7. Patients who are admitted to the hospital from the ED will be eligible for enrollment.\n\nExclusion Criteria:\n\n1. living in a restricted environment (e.g., prison or jail facility, etc.);\n2. currently enrolled in other clinical studies;\n3. anticipated to take other prescribed opioids except buprenorphine for a medical condition longer than three months;\n4. known allergic reaction to buprenorphine;\n5. critically ill or injured;\n6. females with pregnancy (they are anticipated to request a higher level of care).\n7. living outside of Alabama","ALL","19 Years",{"count":79,"type":80},190,"ESTIMATED","INTERVENTIONAL",[83,84],"PHASE1","PHASE2","Opioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patient population. A bundled intervention is proposed, including telehealth, peer support specialist, buprenorphine, and linkage for definitive care, that is designed to increase treatment uptake in this patient population post-ED discharge, reduce repeat opioid overdoses, and end overdose deaths.",[87,88],"Opioid Use Disorder","Opioid Overdose",[90,91,92],"Emergency department","post discharge","buprenorphine","2026-02-19",{"date":95,"type":96},"2026-02-23","ACTUAL",{"date":98,"type":96},"2025-02-13",{"date":100,"type":80},"2030-11-30",{"name":5,"class":6},1]